Radiopharmaceuticals specialist Fujifilm Toyama Chemical has sold development and commercialization rights to its novel small molecule compound, FF-10158, to Advanced Accelerator Applications (AAA), a Novartis company. 4 December 2018
Japan’s Takeda Pharmaceutical has agreed terms for a loan of up to $3.7 billion from Japan Bank, to help finance the acquisition of Shire and reduce current bridging loan commitments. 3 December 2018
Swiss pharma firm Helsinn Group and Mundipharma China Pharmaceutical, the market leader of pain management have received approval from the Chinese National Medical Products Administration (NMPA) for their anti-emetic agent Aloxi (palonosetron). 3 December 2018
Privately-held US skin care company Crown Laboratories has acquired North American distribution rights to five over-the-counter consumer brands from UK pharma major GlaxoSmithKline. 1 December 2018
Torii Pharmaceutical and Japan Tobacco have agreed to terminate the license agreements by which JT grants Torii the exclusive rights to market the six anti-HIV drugs on behalf of US firm Gilead Sciences in Japan and at yesterday’s Torii board of directors meeting the resolution on the termination of the license agreements was adopted. 30 November 2018
Ono Pharmaceutical has filed for Japanese approval of ONO-7643, anamorelin hydrochloride, a candidate for improvement of body weight loss and anorexia in patients with cancer cachexia. 28 November 2018
The multi-billion dollar merger of pharmacy CVS Health and insurer Aetna has been approved by New York state, the last regulatory hurdle for the deal to be finalized. 27 November 2018
CTI BioPharma yesterday announced that the company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medicines Agency. 27 November 2018
ViiV Healthcare, the HIV-focused drugmaker that is majority-owned by UK pharma major GlaxoSmithKline, has won approval in Japan for Juluca (dolutegravir/rilpivirine) for the maintenance treatment of human immunodeficiency virus type 1 (HIV-1) infection. 26 November 2018
Vifor Pharma has sought to shine a light on iron deficiency, a condition that it claims is present in one third of the world’s population. 26 November 2018
Chi-Med, a Chinese biopharma company that is majority owned by the conglomerate CK Hutchison Holdings, has launched Elunate (fruquintinib) in China, in collaboration with its launch partner Eli Lilly. 26 November 2018
Daiichi Sankyo has been granted Priority Review status by the US regulator for the investigational acute myeloid leukemia (AML) therapy quizartinib. 22 November 2018
The USA’s Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for peanut allergy. 21 November 2018
Takeda Pharmaceutical has announced it will issue $5.5 billion of US-dollar denominated senior notes to help pay for its purchase of Shire. 20 November 2018
Ireland-headquartered inflammasone company Inflazome today announces the successful completion of a Series B financing round of 40 million euros ($46 million). 20 November 2018
Japan’s Chugai Pharmaceutical has filed a patent infringement lawsuit against Alexion Pharmaceuticals in the in the US District Court for Delaware. 19 November 2018
Saying it is “in the spirit of providing greater transparency for patients,” US pharma giant Pfizer announced on Friday that it plans to maintain the current list prices for about 90% of its medicines. 17 November 2018
The European Commission has approved French drugmaker Ipsen’s Cabometyx (cabozantinib) as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. 15 November 2018
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024